Letter to the editor: Reply to Kobunai et al.

Pharmacogenomics

Volumn 12, Issue 3, 2011, Pages 309-310

  Roma, Cristin ^a,b   Rachiglio, Anna Maria ^a,b   Normanno, Nicola ^a,b  

^a INT Fondazione Pascale CROM   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;

COLORECTAL CARCINOMA; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG RESPONSE; FALSE NEGATIVE RESULT; GENE MUTATION; GENE SEQUENCE; HUMAN; INTERMETHOD COMPARISON; KRAS GENE; LETTER; MOLECULAR DIAGNOSIS; MUTATION RATE; MUTATIONAL ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; TUMOR GENE;

EID: 79953248115     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.7     Document Type: Letter

References (6)

1. Kobunai T, Watanabe T, Yamamoto Y, Fukusato T: Does a cost-effective approach for the determination of KRAS mutations maximize the patient's beneft in a clinical setting? Pharmacogenomics 12(3), 307-308 (2011).
2. Carotenuto P, Roma C, Rachiglio AM et al.: Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 11(8), 1169-1179 (2010).
3. Tol J, Dijkstra JR, Vink-Borger ME et al.: High sensitivity of both sequencing and real-time PCR ana lysis of KRAS mutations in colorectal cancer tissue. J. Cell. Mol. Med. 14(8), 2122-2131 (2010).
4. Jung A, Baretton G, Dietel M et al.: The German quality assurance system for the molecular-pathological detection of KRAS-mutations in colorectal cancer. ASCO Meeting Abstracts J. Clin. Oncol. 27(15S), 4018 (2009).
5. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F: Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 6(9), 519-527 (2009).
6. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE: Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 16(3), 790-799 (2010).